Table 1.
Demographic parameters and plasma concentration of warfarin and 7-hydroxy warfarin in study participants.
| Parameters | All patients (n = 178) |
|---|---|
| Age (Years) (Mean ± SD) | 40.3 ± 9.6 |
| Gender | |
| Male (%) | 64 (36.0) |
| Female (%) | 114 (64.0) |
| BMI (Kg/m2) | 24.7 ± 31.7 |
| BSA (m2) | 1.53 ± 0.17 |
| Duration of therapy (Years) | 9.6 ± 10.4 |
| Average daily dose of warfarin (mg ± SD) | 4.88 ± 1.63 |
| Mean plasma warfarin (μg/ml ± SD) | 3.47 ± 1.87 |
| Mean plasma 7-hydroxy warfarin (μg/ml ± SD) | 1.25 ± 0.81 |
| Indications for warfarin | |
| Rheumatic Heart Disease (Mitral stenosis) (%) | 116 (65.2) |
| Atrial fibrillation (%) | 12 (6.8) |
| Deep vein thrombosis (%) | 10 (5.6) |
| Coronary Heart Disease (%) | 10 (5.6) |
| Mitral valve replacement (%) | 7 (3.9) |
| Pulmonary embolism (%) | 7 (3.9) |
| Coronary artery disease (%) | 6 (3.4) |
| Aortic valve replacement (%) | 5 (2.8) |
| Cardiomyopathy (%) | 5 (2.8) |